Navicixizumab/Paclitaxel Combo Demonstrates Early Promise in Platinum-Resistant Ovarian Cancer
OncLive,
In Partnership With: The addition of navicixizumab to paclitaxel produced encouraging responses with manageable toxicity in…
In Partnership With: The addition of navicixizumab to paclitaxel produced encouraging responses with manageable toxicity in…
The anti-DLL4/VEGF bispecific antibody navicixizumab showed promising clinical activity when used in combination with…
Overall Clinical Benefit Rate of 85%, Partial Response Rate of 42% and Progression Free Survival of 5.4 Months Observed in…
Overall Clinical Benefit Rate of 85%, Partial Response Rate of 42% and Progression Free Survival of 5.4 Months Observed in…